Full-Time

Regulatory Affairs Manager

Noctrix Health

Noctrix Health

51-200 employees

Prescription wearable neuromodulation for RLS.

Compensation Overview

$150k - $180k/yr

+ Annual bonus

Pleasanton, CA, USA

Hybrid

Hybrid position located at the Pleasanton headquarters.

Bachelor's

Category
Legal & Compliance (1)
Required Skills
FDA Regulations
Risk Management

Get referred to Noctrix Health

See people who can refer or advise you

Requirements
  • A bachelor's degree in Engineering, Life Sciences, Regulatory Affairs, or a related scientific or technical discipline is required.
  • At least 5 years of Regulatory Affairs experience within the medical device industry is required.
  • Demonstrated experience with medical device regulatory submissions, post-market regulatory compliance, and product lifecycle management is required.
  • Strong working knowledge of United States Food and Drug Administration medical device regulations, Medical Device Reporting requirements, and applicable international regulatory frameworks is required.
  • Experience performing regulatory assessments for new product development, design changes, software or firmware updates, labeling changes, and product modifications is required.
  • Experience preparing, supporting, or managing 510(k) submissions is required.
  • Experience supporting international or outside-the-United-States medical device registrations and submissions is required.
  • Knowledge of post-market vigilance requirements, complaint reporting, Medical Device Reporting assessments, and applicable regulatory reporting obligations is required.
  • Experience reviewing promotional, advertising, labeling, or marketing materials for regulatory compliance is required.
  • Strong project management skills with demonstrated ability to coordinate complex regulatory deliverables across multiple functions are required.
  • Strong technical writing skills with experience preparing regulatory documentation and communicating complex information clearly are required.
  • Ability to independently manage multiple regulatory projects, priorities, and deadlines is required.
  • Excellent written and verbal communication skills with the ability to collaborate effectively with internal stakeholders, external partners, and regulatory authorities are required.
  • Strong attention to detail and commitment to regulatory documentation accuracy and compliance are required.
Responsibilities
  • Provide regulatory guidance to cross-functional teams supporting new product development, design changes, risk management, commercialization, and product lifecycle activities.
  • Perform and maintain regulatory assessments for product modifications, software and firmware updates, labeling changes, manufacturing changes, and new product development activities.
  • Serve as the Regulatory Affairs project lead for United States and international regulatory submissions by developing submission strategies, timelines, deliverables, and cross-functional execution plans.
  • Prepare, review, compile, and submit regulatory applications, technical documentation, and responses to regulatory authorities.
  • Support and manage United States regulatory submissions, including 510(k) submissions and other applicable premarket activities.
  • Support international regulatory submissions and registrations across applicable global markets.
  • Maintain product registrations, establishment registrations, regulatory listings, licenses, and other required regulatory records.
  • Track regulatory commitments, submission milestones, renewals, and reporting requirements to ensure timely completion.
  • Serve as a primary Regulatory Affairs liaison with external partners, including European Authorized Representatives, regulatory consultants, and applicable regulatory authorities.
  • Review and approve promotional, advertising, labeling, and marketing materials to ensure compliance with applicable regulations and approved product claims.
  • Lead post-market regulatory reporting and vigilance activities, including assessment, submission, tracking, and documentation of reportable events.
  • Perform Medical Device Reporting assessments and support reporting determinations in accordance with applicable regulatory requirements.
  • Collaborate with Quality, Clinical Affairs, and Post-Market Surveillance teams to support complaint trend reporting, periodic safety update reports, periodic regulatory reports, and other post-market deliverables.
  • Administer and maintain regulatory electronic submission platforms and accounts, including the FDA Electronic Submission Gateway, WebTrader, and other applicable regulatory systems.
  • Monitor evolving United States and international regulatory requirements and assess potential impacts to products, processes, registrations, and regulatory strategies.
  • Communicate regulatory changes, risks, requirements, and recommendations to cross-functional stakeholders and leadership.
  • Support regulatory inspections, audits, agency inquiries, and Quality System activities related to Regulatory Affairs.
  • Identify opportunities to improve regulatory processes, documentation, tracking, and cross-functional execution as the organization grows.
Desired Qualifications
  • An advanced degree in Regulatory Affairs, Engineering, Life Sciences, or a related discipline is preferred.
  • Regulatory Affairs Certification is preferred.
  • Experience within a startup or growth-stage medical device organization is preferred.
  • Experience serving as the regulatory lead or project manager for successful 510(k) submissions is preferred.
  • Experience with European Union Medical Device Regulation and international medical device registrations is preferred.
  • Experience supporting connected, wearable, software-enabled, or electro-medical devices is preferred.
  • Experience with software and firmware change assessments is preferred.
  • Experience preparing or supporting periodic safety update reports and other post-market regulatory deliverables is preferred.
  • Experience interacting directly with the FDA or other regulatory authorities is preferred.
  • Experience supporting FDA inspections, notified body audits, or other regulatory inspections is preferred.

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reported about $24 million annual run-rate revenue before closing, already commercializing.
  • CMS issued dedicated HCPCS codes and payment in 2024, reducing patient access friction.
  • ResMed can cross-sell Nidra through existing sleep clinics, HME partners, and international distribution.

What critics are saying

  • ResMed must integrate Noctrix by late 2026 while preserving sales momentum and reimbursement.
  • RLS prescriptions depend on sleep physicians and HMEs; coverage changes would choke adoption quickly.
  • If Nidra stalls below ResMed's expectations, the asset becomes a small, deprioritized portfolio experiment.

What makes Noctrix Health unique

  • Nidra is FDA De Novo-cleared, drug-free TOMAC for medication-refractory RLS.
  • AASM guidelines recognized peroneal nerve stimulation in 2024, validating Noctrix's mechanism.
  • ResMed completed the $340 million acquisition on June 1, 2026, giving channel reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.